Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis. (31st December 2022)

• Record Type: Journal Article
• Authors: Diebold, Martin; Meola, Marco; Purushothaman, Srinithi; Siewert, Lena K; Pössnecker, Elisabeth; Roloff, Tim; Lindberg, Raija LP; Kuhle, Jens; Kappos, Ludwig; Derfuss, Tobias; Egli, Adrian; Pröbstel, Anne-Katrin
• Is Part Of: Gut microbes. Volume 14:Isuse 1(2022)
• Publication Date: 2022-12-31
• Subjects: Multiple sclerosis -- microbiome -- dimethyl fumarate -- lymphopenia -- metabolomics -- therapeutic biomarker; Gastrointestinal system -- Microbiology -- Periodicals; Microbiology -- Periodicals; Intestine, Small -- Periodicals; 616.3
• DOI: 10.1080/19490976.2022.2147055
• Languages: English
• ISSNs: 1949-0984

Abstract

ABSTRACT: Mounting evidence points towards a pivotal role of gut microbiota in multiple sclerosis (MS) pathophysiology. Yet, whether disease-modifying treatments alter microbiota composition and whether microbiota shape treatment response and side-effects remain unclear. In this prospective observational pilot study, we assessed the effect of dimethyl fumarate (DMF) on gut microbiota and on host/microbial metabolomics in a cohort of 20 MS patients. Combining state-of-the-art microbial sequencing, metabolome mass spectrometry, and computational analysis, we identified longitudinal changes in gut microbiota composition under DMF-treatment and an increase in citric acid cycle metabolites. Notably, DMF-induced lymphopenia, a clinically relevant safety concern, was correlated with distinct baseline microbiome signatures in MS patients. We identified gastrointestinal microbiota as a key therapeutic target for metabolic properties of DMF. By characterizing gut microbial composition as a candidate risk factor for DMF-induced lymphopenia, we provide novel insights into the role of microbiota in mediating clinical side-effects.